1)Jonker DJ, O’Callaghan CJ, Karapetis CS, et al : Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048,2007
2)Spano JP, Lagorce C, Atlan D, et al : Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 16:102-108,2005
3)Chung KY, Shia J, Kemeny NE, et al : Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23:1803-1810,2005
4)Karapetis CS, Khambata-Ford S, Jonker DJ, et al : K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765,2008
5)Watanabe T, Yoshino T, Uetake H, et al : KRAS mutational status in Japanese patients with colorectal cancer : results from a nationwide, multicenter, cross-sectional study. Jpn J Clin Oncol 43:706-712,2013
6)Douillard JY, Oliner KS, Siena S, et al : Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023-1034,2013
7)Yoshino T, Muro K, Yamaguchi K, et al : Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer : Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study. EBioMedicine 2:317-323,2015
8)日本臨床腫瘍学会:大腸がん患者におけるRAS遺伝子(KRAS/NRAS遺伝子)変異の測定に関するガイダンス,第2版.2014年4月,2014